½ÃÀ庸°í¼­
»óǰÄÚµå
1820269

¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå º¸°í¼­ : À¯Çü, ¿ëµµ, Áö¿ªº°(2025-2033³â)

Bifurcation Lesions Market Report by Types (One-Stent, Two-Stent), Application (Coronary Vascular, Peripheral Vascular), and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 139 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå ±Ô¸ð´Â 2024³â 25¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â¿¡´Â 38¾ï ´Þ·¯¿¡ À̸£°í, 2025-2033³âÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 4.4%°¡ µÉ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ºÐÁöº´º¯Àº Áß¿äÇÑ °ç°¡Áö(SB)ÀÇ ½ÃÀÛ ºÎºÐ¿¡ ÀÎÁ¢ÇÑ °ü»ó µ¿¸ÆÀÇ ÇùÂøÀ» ÀǹÌÇÕ´Ï´Ù. È寮·¯Áø Ç÷·ù¿Í ³ôÀº Àü´Ü ÀÀ·ÂÀ¸·Î ÀÎÇØ µ¿¸Æ°æÈ­¼º ÇöóÅ©°¡ ¹ß»ýÇϱ⠽±½À´Ï´Ù. ºÐ¼®, ÀýÂ÷ ½Ã°£, X¼± Á¶»ç, Àå±â °æ°ú °üÂû µîÀÇ ±â¼úÀ» »ç¿ëÇÏ¿© Ä¡·áµË´Ï´Ù. ¶ÇÇÑ, 3Â÷¿ø(3D) Ç÷°ü Á¶¿µ ¹× ´ÙÁß ½½¶óÀ̽º CT°¡ ºÐ±â°¢ ÃøÁ¤¿¡ ÀÌ¿ëµË´Ï´Ù. Àåºñ, ¿µ»ó Áø´Ü, º¸Á¶ ¾à¹° ¿ä¹ý, Ç÷°ü Á¢±ÙÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ºÐÁöº´º¯ÀÇ º¹ÀâÇÑ »ç·Ê °ü¸®°¡ ¼¼°èÀûÀ¸·Î °¡´ÉÇØÁö°í ÀÖ½À´Ï´Ù.

ºÐÁöº´º¯ ½ÃÀå µ¿Çâ :

°ü»ó µ¿¸Æ Áúȯ(CAD) Áõ°¡´Â ºÐÁöº´º¯ÀÇ °³¹ß À§ÇèÀ» ³ôÀÔ´Ï´Ù. À̰ÍÀº ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ ¿ä¼Ò Áß ÇϳªÀÔ´Ï´Ù. ÀÌ ¿Ü¿¡µµ Çõ½ÅÀûÀÎ ±â±â ½ÂÀÎ, º¸Çè Àû¿ë ¹üÀ§ È®´ë, ¿µ»ó Áø´Ü ¾ç½Ä Çâ»ó µî ½ÃÀåÀÇ ¼ºÀåÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ÀÇ·á ÁúȯÀ» ¹ßº´Çϱ⠽¬¿î ³ë³â Àα¸°¡ Áõ°¡Çϰí ÀÖ´Â °Í, »óȯÀ» À§ÇØ °¢±¹ Á¤ºÎ°¡ ½Ç½ÃÇϰí ÀÖ´Â Áö¿øÃ¥ÀÌ ½ÃÀå ¼ºÀåÀ» ÁöÁöÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á °ü±¤ Áõ°¡, ³·Àº ħ½À(MI) ÀýÂ÷¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °Ç°­ °ü¸® ÀÎÇÁ¶ó °³¼± µîÀº ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ´Ù¸¥ ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù. À̿ʹ º°µµ·Î, »õ·Î¿î Ä¡·á ±â¼ú¿¡ °üÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, SB Æó»öÀÇ À§ÇèÀÌ ³ô°Å³ª Ä¡¸íÀûÀÎ °á°ú¸¦ ÃÊ·¡ÇÏ´Â º¹ÀâÇÑ ºÐÁöº´º¯¿¡ ´ëÇÑ Szabo 2 ½ºÅÙÆ® ¹æ¹ýÀÇ È¿´ÉÀ» ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ½ºÅÙÆ®¿Í dz¼±¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ÀÓ»ó½ÃÇè°ú ¼÷·ÃµÈ ÀÇ·á Á¾»çÀÚ Áõ°¡°¡ ÇÔ²², ºÐÁöº´º¯ Ä¡·á¿¡ µû¸¥ À§ÇèÀÌ °¨¼ÒÇÏ°í ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2024³â ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå ±Ô¸ð´Â?
  • 2025-2033³â ¼¼°è ºÐÁöº´º¯ ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå¿¡¼­ COVID-19ÀÇ ¿µÇâÀº?
  • ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿äÀÎÀº?
  • ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå¿¡¼­ ¿ëµµº° ±¸ºÐÀº?
  • ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå¿¡¼­ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ºÐÁöº´º¯ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : À¯Çüº°

  • 1 ½ºÅÙÆ®
  • 2 ½ºÅÙÆ®

Á¦7Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

  • °ü»óµ¿¸ÆÇ÷°ü
  • ¸»ÃÊ Ç÷°ü

Á¦8Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå SWOT ºÐ¼®

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Boston Scientific Corporation
    • Cardinal Health
    • Medtronic plc
    • Spectranetics(Koninklijke Philips NV)
    • Terumo Corporation
JHS

The global bifurcation lesions market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.4% during 2025-2033.

A bifurcation lesion refers to the narrowing of the coronary artery adjacent to the origin of a significant side branch (SB). It is prone to develop atherosclerotic plaque due to turbulent blood flow and high shear stress. It is treated using techniques like analysis, procedure duration, X-ray exposure, and long-term follow-up. Moreover, three-dimensional (3D) angiography and multi-slice computed tomography are utilized for measuring the bifurcation angles. With the advances in devices, imaging, adjunctive pharmacotherapy, and vascular access, the management of complex cases of bifurcation lesions is becoming possible worldwide.

Bifurcation Lesions Market Trends:

A significant rise in the occurrence of coronary artery disease (CAD) is increasing the risk of developing bifurcation lesions. This represents one of the key factors bolstering the market growth. Besides this, the approval of innovative devices, increasing insurance coverage, and improving imaging modalities are also strengthening the market growth. Moreover, the rising geriatric population, which is more likely to develop medical ailments, along with supportive initiatives undertaken by governments of various countries for reimbursement, is supporting the market growth. The increasing medical tourism, the escalating demand for minimally invasive (MI) procedures and the improving healthcare infrastructure are some of the other factors contributing to the growth of the market. Apart from this, the ongoing research on novel treatment techniques is driving the market. For instance, researchers are studying the effectiveness of the Szabo 2-stent technique for complex bifurcations lesions with high compromise risk or fatal consequences of SB occlusion. Furthermore, a wide range of clinical trials on stents and balloons, in confluence with the increasing number of skilled healthcare professionals, is anticipated to decrease risks associated with bifurcation lesions treatment and influence the market positively.

Key Market Segmentation:

Breakup by Types:

  • One-Stent
  • Two-Stent

Breakup by Application:

  • Coronary Vascular
  • Peripheral Vascular

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, Cardinal Health, Medtronic plc, Spectranetics (Koninklijke Philips N.V.) and Terumo Corporation.

Key Questions Answered in This Report

  • 1.What was the size of the global bifurcation lesions market in 2024?
  • 2.What is the expected growth rate of the global bifurcation lesions market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global bifurcation lesions market?
  • 4.What are the key factors driving the global bifurcation lesions market?
  • 5.What is the breakup of the global bifurcation lesions market based on the application?
  • 6.What are the key regions in the global bifurcation lesions market?
  • 7.Who are the key players/companies in the global bifurcation lesions market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Bifurcation Lesions Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Types

  • 6.1 One-Stent
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Two-Stent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Coronary Vascular
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Peripheral Vascular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Boston Scientific Corporation
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Cardinal Health
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Medtronic plc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Spectranetics (Koninklijke Philips N.V.)
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Terumo Corporation
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦